Buechel M et al. reported PTC-2 as a first-generation inhibitor of Bmi-1, which may represent a promising targeted approach for patients with advanced or recurrent endometrial cancer by utilizing anti-Bmi-1 strategies [18]. The gene discussed is BMI1; the disease is endometrial cancer.